The Indemnity Calculus For Covid-19 Vaccines, India’s Path Ahead

Legal experts discuss the intricacies around pharma’s demand for indemnity, a key sticking point for supplies of COVID-19 vaccines from Pfizer and Moderna, and the path forward for countries like India.  

indemnity
To Indemnify Or Not, That Is the Question • Source: Alamy

Developing nations like India should consider consenting to pharma’s indemnity demand, albeit with sharp drafting of the nuances and secure supplies of COVID-19 vaccines, given that a large part of the population is yet to get inoculated, an assessment by legal and other experts suggests.

These are, after all, extraordinary times and "indemnity hesitancy" may come at the cost of losing out on procuring the...

More from Global Vision

More from In Vivo